Reporting back (a bit late) from GI ASCO 2015.
Abstract:Tumor profiling for distinct molecular alterations.
Focused on IDH 1 and IDH 2 which are metabolic enzymes found in several malignancies. These enzymes help break down nutrients and generate the energy for cells. However; once mutated, IDH creates molecules which interfere with the genetic profiling; cells don’t mature but rather they multiply rapidly ultimately leading to malignant tumors.
Another study demonstrated that extrahepatic CCA had the highest rate of KRAS mutation whereas intrahpetic CC which showed evidence of the highest rate of IDH -1 mutations.
HER2 mutations were higher in extrahepatic CCA than in intrahepatic CCA suggesting that HER2 targeted therapy may prove positive for this subgroup of patients.
It also is suggested that further studies may prove that intrahepatic CCA may identify additional molecular subgroups.
With continued profiling studies, we will gain a better insight into the disease biology which then should lead to sensitivity identification for distinct therapies.
The below abstract on genomic profiling of biliary cancers showed responses to drugs on the market or drugs under evaluation in clinical trials.
Note: IHCCA (intrahepatic) EHCCA (extrahepatic) GBCA (gallbladder)
Hugs to all,